Business Wire

BONA

1.12.2021 08:32:10 CET | Business Wire | Press release

Share
Bona Germany Welcomes Emission-Free, Scania Electric Truck to Facility in Limburg

Bona® , a global, sustainably-driven company that supplies products for installing, renovating, maintaining, and restoring premium floors, and Scania, one of the world's leading providers of transport solutions, hosted an event yesterday to welcome Bona’s first electric truck to its facility in Limburg, Germany. The Scania innovated truck is from the Scania P series and will offer an emission-free transport system for Bona’s operations in Limburg and the surrounding area. It is the first of its kind to be operated in Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005952/en/

"Bona is committed to incorporating and pursuing sustainable products, systems, and practices throughout the company and the new Scania electric truck is an important milestone in our journey to a greener future,” said Dr. Thomas Brokamp, Managing Director, Bona Germany. “Scania advised us well on the choice of our electric vehicle and gave us a good introduction to this new technology. The Scania electric truck is perfectly tailored to our needs and areas of operation.” The battery-electric truck will act as a city shuttle, making multiple trips a day to transport finished products from the production plant in the south of the city to the distribution center in the north, just under six kilometers away. Approximately 21 euro pallets can be accommodated in the loading area on each tour.

A POWERFUL DRIVE SYSTEM AND COMFORTABLE RIDE

The new model in the Scania P series, called the Scania 25 P, was specially designed for inner-city use and is characterized by comfortable access to the cab and excellent traffic visibility. The number in the model designation indicates the power that the truck travels, up to 230 kW (312 hp) rated engine power, which is enough power to move the three-axle truck's permissible weight of 26 tons with ease.

"The electric powertrain shines, especially at low engine speeds and in starting situations, with significantly better acceleration and more tractive power compared to a diesel truck," said Christian Hottgenroth, Director of Truck Sales, Scania Germany Austria. “In practice, drivers can therefore look forward to rapid acceleration and short response times from the drive.”

The Scania 25 P stores the energy for propulsion in five lithium-ion batteries, each with a capacity of 33 kW/h. "The electric range depends primarily on the factors of driving style, load, as well as topography," Hottgenroth explained further. Under optimal conditions, the drive batteries with the total capacity of 165 kW/h are designed for a range of up to 110 kilometers, while 70 to 90 kilometers can be expected in real driving conditions. For Bona’s use in the city of Limburg, which will average approximately 50 kilometers per day, the power is completely sufficient for the planned operating profile.

POWERED WITH SUSTAINABLE ENERGY

Because Bona’s Limburg facility is equipped with solar panels, the new Scania truck will be fueled by green electricity generated by a powerful photovoltaic system on the roof of the large hall. The fully electric truck is charged with direct current and is equipped with a charging capacity of 130 kW, which allows the batteries to be fully charged in about an hour at 20 percent capacity. If more range is required, a stop of half an hour at the charging station is enough to charge energy for another 50 or 60 kilometers.

“Moving to an emission-free vehicle is an important part of our broader sustainability journey and part of our commitment to be a good citizen. Due to high traffic the city of Limburg has a problem with excessively high nitrogen dioxide levels. The main source are diesel vehicles, and it is now extremely likely a ban for these vehicles is coming 1st of April 2022 for Limburg. With our emission-free truck we can make a valuable contribution in Limburg to lower nitrogen dioxide levels and to global decarbonization," said Dr. Brokamp. The fact that the electric truck from Scania also runs locally with zero emissions and is virtually noise-free due to its low-noise drive are also benefits of the all-electric truck.

Bona is in the process of finalizing the electric charging station, which is slated for completion by early 2022.

ABOUT BONA

Bona is a family-owned, sustainably-driven company that supplies products for installing, renovating, maintaining, and restoring premium floors. Founded in 1919, Bona was the first in the industry to offer a full system of waterborne hardwood floor finishing and floor care products. Today, Bona offers products for most premium floor surfaces including wood, tile, vinyl, resilient, rubber, and laminate. Bona’s turnover is 3.1bn SEK (EUR 307 million) 2020. The head office is in Malmö, Sweden, and the company is represented globally by its 17 subsidiaries, 70 distributors, 600 employees, and 5 factories. For more, visit www.bona.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye